

Date: 16th May, 2022

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai - 400 001

Dear Sir/Madam,

Sub.: Disclosure on Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosures Requirements) Regulations, 2015 (“Listing Regulations, 2015”)

With reference to the captioned matter, we would like to inform that pending the release of XBRL template in the new format prescribed by SEBI vide its Circular dated 22nd November, 2021 on Disclosure obligations of listed entities in relation to Related Party Transactions and based on the verbal guidance provided by the stock exchanges, we enclose herewith scanned copy of disclosures on Related Party Transactions for the half year ended 31st March, 2022.

We will upload the said disclosures in XBRL as and when the template is released by the stock exchanges.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited



Charandeep Singh Saluja
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003, INDIA • TEL : +91-265-2280550 • FAX : +91-265-2282837
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in
CIN : L24230GJ2010PLC061123

Alembic Pharmaceuticals Limited - Disclosure of Related Party Transactions for the half year ended 31st March, 2022

(Rs. in Crores)

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken									
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/advance / inter-corporate deposit/investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)	
1	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Subsidiary	Reimbursement Paid	0.83	0.83	2.23	0.11									
2	Alembic Pharmaceuticals Ltd.		Alembic Global Holding SA		Subsidiary	Withdrawal of Corporate Guarantee	73.11	73.11	73.11										
3	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Subsidiary	Sale of Goods	940.58	940.58	272.15	940.56									
4	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Subsidiary	Reimbursement Paid	20.64	20.64											
5	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Subsidiary	Reimbursement Received	0.37	0.37											
6	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Subsidiary	Guarantee Commission Received	0.19	0.19											
7	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Inc.		Subsidiary	Withdrawal of Corporate Guarantee	58.48	58.48	131.58	75.79									
8	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Europe Ltd.		Fellow Subsidiary	Reimbursement Paid	0.41	0.41	0.06	0.46									
9	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Australia Pty Ltd.		Fellow Subsidiary	Reimbursement Paid	2.05	2.05	0.00	2.05									
10	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Rent Received	0.22	0.22											



Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/advance / inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
11	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Investment in Unsecured Non-Convertible Debentures	37.00	37.00	377.00	414.00				Investment	12%	10 years from the date of first allotment	Unsecured	Investment as per Securities Subscription Agreement including amendments thereto
12	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Investment in Unsecured Non-Convertible Debentures			200.00	200.00								
13	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Investment in Secured Non-Convertible Debentures			300.00	300.00								
14	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Reimbursement Received	0.10	0.10										
15	Alembic Pharmaceuticals Ltd.		Aleor Dermaceuticals Ltd.		Subsidiary	Deposit Taken			0.06	0.06								
16	Alembic Pharmaceuticals Ltd.		Incozen Therapeutics Pvt. Ltd.		Associate	Sale of Goods	0.05	0.05	0.03	0.00								
17	Alembic Pharmaceuticals Ltd.		Rhizen Pharmaceuticals AG		Associate	Sale of Goods	51.57	51.57	21.87	26.30								
18	Alembic Pharmaceuticals Ltd.		Rhizen Pharmaceuticals AG		Associate	Service Rendered	0.30	0.30										
19	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Reimbursement Paid	0.01	0.01										
20	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Rent paid	0.05	0.05										
21	Alembic Pharmaceuticals Ltd.		Alembic City Ltd.		Promoter Group	Deposit Given			0.03	0.03								



Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/advance / inter-corporate deposit/investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
22	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Purchase of Goods	2.78	2.78	3.22	4.03								
23	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Reimbursement Paid	0.69	0.69										
24	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Rent paid	4.96	4.96										
25	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Sale of Goods	0.41	0.41										
26	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Service Received	7.72	7.72										
27	Alembic Pharmaceuticals Ltd.		Alembic Ltd.		Promoter	Deposit Given			2.75	2.75								
28	Alembic Pharmaceuticals Ltd.		Paushak Ltd.		Promoter Group	Purchase of Goods	0.86	0.86	0.23	0.15								
29	Alembic Pharmaceuticals Ltd.		Paushak Ltd.		Promoter Group	Rent paid	0.00	0.00										
30	Alembic Pharmaceuticals Ltd.		Paushak Ltd.		Promoter Group	Reimbursement Received	0.22	0.22										
31	Alembic Pharmaceuticals Ltd.		Rakshak Services Pvt. Ltd.		Other Related Parties	Service Received	0.50	0.50	0.00	0.33								
32	Alembic Pharmaceuticals Ltd.		Shreno Ltd.		Promoter Group	Purchase of Goods	0.09	0.09	0.01	0.06								
33	Alembic Pharmaceuticals Ltd.		Shreno Ltd.		Promoter Group	Rent paid	0.28	0.28										
34	Alembic Pharmaceuticals Ltd.		Shreno Publications Ltd.		Promoter Group	Purchase of Goods	17.38	17.38	2.43	2.28								
35	Alembic Pharmaceuticals Ltd.		Bhailal Amin General Hospital		Promoter Group	Service Received	2.63	2.63	0.00	0.23								
36	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited Provident Fund		Other Related Parties	Post Retirement benefits	36.82	36.82	6.36	6.11								
37	Alembic Pharmaceuticals Ltd.		Alembic CSR Foundation		Other Related Parties	CSR Contribution	14.27	14.27										



Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance / inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
38	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited Super Annuation Scheme		Other Related Parties	Post Retirement benefits	2.13	2.13										
39	Alembic Pharmaceuticals Ltd.		Shreno Engineering Ltd.		Promoter Group	Fixed Asset purchase	2.81	2.81	0.03	1.51								
40	Alembic Pharmaceuticals Ltd.		Shreno Engineering Ltd.		Promoter Group	Sale of Goods	0.29	0.29										
41	Alembic Pharmaceuticals Ltd.		Shreno Engineering Ltd.		Promoter Group	Service Received	0.01	0.01										
42	Alembic Pharmaceuticals Ltd.		Alembic Pharmaceuticals Limited EGGS		Other Related Parties	Post Retirement benefits	10.50	10.50										
43	Alembic Pharmaceuticals Ltd.		Archana Niranjn Hingorani		Key Managerial Personnel	Sitting Fees		0.03										
44	Alembic Pharmaceuticals Ltd.		Krishnapuram Gopalakrishnan Ramanathan		Key Managerial Personnel	Sitting Fees		0.03										
45	Alembic Pharmaceuticals Ltd.		Paresh Manil Saraiya		Key Managerial Personnel	Sitting Fees		0.03										
46	Alembic Pharmaceuticals Ltd.		Pranav Natverial Parikh		Key Managerial Personnel	Sitting Fees		0.03										
47	Alembic Pharmaceuticals Ltd.		Ashok Kumar Barat		Key Managerial Personnel	Sitting Fees		0.02										
48	Alembic Pharmaceuticals Ltd.		Archana Niranjn Hingorani		Key Managerial Personnel	Commission		0.12		0.12								
49	Alembic Pharmaceuticals Ltd.		Krishnapuram Gopalakrishnan Ramanathan		Key Managerial Personnel	Commission		0.12		0.12								



Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/advance / inter-corporate deposit/investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
50	Alembic Pharmaceuticals Ltd.		Paresh Manilal Saraiya		Key Managerial Personnel	Commission		0.12		0.12								
51	Alembic Pharmaceuticals Ltd.		Pranav Natverlal Parikh		Key Managerial Personnel	Commission		0.12		0.12								
52	Alembic Pharmaceuticals Ltd.		Ashok Kumar Barat		Key Managerial Personnel	Commission		0.04		0.04								
53	Alembic Pharmaceuticals Ltd.		Chirayu Ramanbhai Amin		Key Managerial Personnel	Short term employee benefits		10.56		20.00								
54	Alembic Pharmaceuticals Ltd.		Pranav Chirayu Amin		Key Managerial Personnel	Short term employee benefits		9.61		8.00								
55	Alembic Pharmaceuticals Ltd.		Shaunak Chirayu Amin		Key Managerial Personnel	Short term employee benefits		9.61		8.00								
56	Alembic Pharmaceuticals Ltd.		Udit Chirayu Amin		Key Managerial Personnel	Short term employee benefits		3.79										
57	Alembic Pharmaceuticals Ltd.		Chirayu Ramanbhai Amin		Key Managerial Personnel	Post employment benefits		0.24										
58	Alembic Pharmaceuticals Ltd.		Pranav Chirayu Amin		Key Managerial Personnel	Post employment benefits		0.24										
59	Alembic Pharmaceuticals Ltd.		Shaunak Chirayu Amin		Key Managerial Personnel	Post employment benefits		0.24										



Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments				
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/issuance of debt/any other etc.)	Cost	Tenure	Nature (loan/advance / inter-corporate deposit/investment)	Interest Rate (%)	Tenure	Secured/unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
60	Alembic Pharmaceuticals Ltd.		Charandeep Singh Saluja		Key Managerial Personnel	Short term employee benefits	0.04											
61	Alembic Pharmaceuticals Ltd.		Charandeep Singh Saluja		Key Managerial Personnel	Post employment benefits	0.07											
62	Alembic Pharmaceuticals Ltd.		Rajkumar Shreeram Baheti		Key Managerial Personnel	Short term employee benefits	2.48											
63	Alembic Pharmaceuticals Ltd.		Rajkumar Shreeram Baheti		Key Managerial Personnel	Post employment benefits	0.16											

For Alembic Pharmaceuticals Limited

Authorized Signatory

